Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07225543 · ClinicalTrials.gov registry record · Phase 2
2-HOBA in Systemic Lupus Erythematosus
A Phase 2 study, sponsored by Vanderbilt University Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT07225543 is a Phase 2 study that is actively recruiting participants, run by Vanderbilt University Medical Center. The registered enrollment target is 42 participants.
The verdict
NCT07225543, a Phase 2 study, is actively recruiting participants, sponsored by Vanderbilt University Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
This is a phase II randomized, placebo-controlled, double-blind, cross-over study to determine the effect of isolevuglandin (IsoLG) scavenging by 2-HOBA on blood pressure and immune activation in patients with SLE. 42 patients with stable SLE will be randomized to treatment sequence to receive placebo or 500mg 2-HOBA three times a day for 8 weeks followed by a 4 week washout and then 8 weeks of the other agent. Primary outcome measures include change in 24-hour blood pressure and NETosis. This study will provide mechanistic information on the role of IsoLGs in autoimmune disease-associated hypertension and immune activation.
Interventions
- DRUG Placebo
- DRUG 2-HOBA acetate (2-Hydroxybenzlamine acetate)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2026-05-15 |
| Est. Completion | 2030-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07225543
The ClinicalTrials.gov registry entry for NCT07225543 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07225543 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07225543 about?
NCT07225543 is a clinical study titled "2-HOBA in Systemic Lupus Erythematosus". This is a phase II randomized, placebo-controlled, double-blind, cross-over study to determine the effect of isolevuglandin (IsoLG) scavenging by 2-HOBA on blood pressure and immune activation in patients with SLE. 42 patients with stable SLE will be randomized to treatment sequence to receive place...
What is the current status of trial NCT07225543?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2026-05-15. Estimated completion is 2030-07-31.
What interventions are being tested in trial NCT07225543?
The interventions under investigation include: Placebo (DRUG), 2-HOBA acetate (2-Hydroxybenzlamine acetate) (DRUG).
Who is sponsoring clinical trial NCT07225543?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.